Latest filings (excl ownership)
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
D
$765.00 k in other securities, sold $76.50 k, 2 investors
15 Feb 24
8-K
Regulation FD Disclosure
28 Nov 23
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
13 Nov 23
8-K
Regulation FD Disclosure
9 Nov 23
8-K
KAYS’ Oregon Based Psilocybin Treatment Center is on track to be the first of its kind operated by a U.S. Public Company
23 Oct 23
8-K
State-of-the-Art Facility to Offer Access to Psilocybin Treatments
3 Oct 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
22 May 23
10-K/A
2022 FY
Annual report (amended)
19 May 23
8-K
Other Events
15 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
27 Apr 23
NT 10-K
Notice of late annual filing
29 Mar 23
8-K
Completion of Acquisition or Disposition of Assets
13 Mar 23
8-K
Other Events
17 Feb 23
8-K
Other Events
30 Jan 23
10-Q
2022 Q3
Quarterly report
21 Nov 22
NT 10-Q
Notice of late quarterly filing
14 Nov 22
S-8
Registration of securities for employees
15 Sep 22
10-Q
2022 Q2
Quarterly report
22 Aug 22
NT 10-Q
Notice of late quarterly filing
15 Aug 22
8-K
Other Events
7 Jul 22
10-Q
2022 Q1
Quarterly report
18 May 22
NT 10-Q
Notice of late quarterly filing
16 May 22
10-K
2022 FY
Annual report
18 Apr 22
NT 10-K
Notice of late annual filing
30 Mar 22
8-K
Departure of Directors or Certain Officers
29 Dec 21
10-Q
2021 Q3
Quarterly report
22 Nov 21
8-K
Completion of Acquisition or Disposition of Assets
27 Oct 21
10-Q
2021 Q2
Quarterly report
16 Aug 21
8-K
Entry into a Material Definitive Agreement
28 Jul 21
10-Q
2021 Q1
Quarterly report
17 May 21
10-K
2020 FY
Annual report
31 Mar 21
8-K
Regulation FD Disclosure
19 Mar 21
8-K
Other Events
5 Feb 21
8-K
Regulation FD Disclosure
14 Jan 21
Latest ownership filings
No filings